Fredun Pharmaceuticals Ltd.
Snapshot View

421.70 -5.05 ▼-1.2%

29 July 2021, 04:00:00 P.M.
Volume: 3,977

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.fredungroup.com
Financial Indicators
Market Cap 168.22 Cr.
Earnings per share (EPS) 5.05 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 83.49 Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 107.96 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.91 Calculated using Price: 421.65
Dividend Yield 0.16 Period Ending 2020-03
No. of Shares Subscribed 0.40 Cr. 3,989,634 Shares
FaceValue 10
Company Profile

Fredun Pharmaceuticals with its over 2 decades of experience in manufacturing various pharmaceutical formulations has built a good reputation as a reliable and ethical company having buyers which not only include leading Pharma companies of India but also across Africa, South East Asia and CIS countries.

Fredun has disciplined and highly efficient personnel contributing to various activities encompassing corporate management, finance, research and development, production and marketing. Their teams strive to maximize productivity and minimize costs at all levels before and after production. They also have multiple management teams which work hand in hand to eliminate the possibility of managerial errors and enhance the overall output.

Exporting to several countries across Asia and Africa such as Uganda, Nigeria, Ghana, Congo, Kenya, Sierra Leone, Monrovia, Sri Lanka, and Vietnam for the past several years, Fredun has created good will of immense value. The company has a highly satisfied clientele, satisfaction derived from our consistent product quality and attractive presentation.

Fredun insists on Total Quality Assurance throughout its operations. The company has multiple quality control systems which help us produce quality products batch after batch. The company first obtained its World Health Organization GMP certificate in the year 1996.The company has also been awarded the ISO 9001-2008 for quality standards. 

Business area of the company:

The company is engaged in manufacturing of pharmaceutical products.

Products:

  • Tablets:
    -  Anti-Bacterial
    - Anti-Malarial
    - Anti-Diabetic
    - Others
  • ? Capsules:
    - Anti-Bacterial
    - Others
  • ? Dry Syrups:
    -  Anti-Bacterial
    - Anti-Malarial


Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.18%
1 Week
+1.47%
1 Month
+1.82%
3 Month
+1.24%
6 Month
-7.73%
1 Year
+77.89%
2 Year
+25.21%
5 Year
+1586.80%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -9.51 0.31 9.79 9.68 33.46 33.88 13.02 14.59 4.74
Return on Capital Employed (%) 8.47 12.40 14.50 14.23 24.67 18.16 15.90 20.56 10.36
Return on Assets (%) -2.10 0.05 1.50 1.26 3.23 2.88 2.59 4.84 1.60

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 3 3 3 3 4 7 22 39 41
Non Curr. Liab. 2 2 3 4 7 8 4 13 14
Curr. Liab. 8 10 12 16 32 40 53 53 78
Minority Int.
Equity & Liab. 13 15 18 23 43 56 79 105 133
Non Curr. Assets 7 7 8 10 15 21 28 32 32
Curr. Assets 6 8 10 13 28 35 51 73 101
Misc. Exp. not W/O 0
Total Assets 13 15 18 23 43 56 79 105 133

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 12 15 21 25 42 57 60 97 113
Other Income 1 0 0 0 1 2 0 1 1
Total Income 12 15 22 26 43 59 60 98 113
Total Expenditure -11 -14 -20 -24 -38 -53 -54 -87 -105
PBIDT 1 1 2 2 5 5 6 11 9
Interest -1 -1 -1 -1 -2 -2 -2 -3 -4
Depreciation 0 0 -1 -1 -1 -1 -1 -1 -2
Taxation 0 0 0 -1 -1 -1 -2 -1
Exceptional Items 0 0
PAT 0 0 0 0 1 1 2 4 2

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 -1 2 3 4 17 1 -11
Cash Fr. Inv. -1 -2 -3 -6 -7 -8 -5 -1
Cash Fr. Finan. 0 2 1 3 3 -8 4 14
Net Change 0 0 0 1 -1 1 0 2
Cash & Cash Eqvt 1 0 1 1 1 1 1 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 52.04 52.04 52.04 52.04 52.04 52.04 52.04 52.04 52.04
Public 47.96 47.96 47.96 47.96 47.96 47.96 47.96 47.96 47.96
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 3.85 3.85 5.54 5.54 5.54 5.54 5.54 5.54 0.00

Announcements View Details

Mon, 12 Jul 2021
Shareholding for the Period Ended June 30 2021
Fredun Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Sat, 03 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Ankita Joshi
Designation :- Company Secretary and Compliance Officer
Thu, 01 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance to Regulation 47(1)(b) of SEBI Listing Regulations 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Quarter and Year ended March 31 2021; as approved by the Board in its Meeting held on Monday June 28 2021; published in Business Standard & Mumbai Lakshadeep newspaper(s) on Wednesday June 30 2021.

Technical Scans View Details

Thu, 29 Jul 2021
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Closing Near 100 EMA Closing Near 100 EMA
Close Crossing 50 EMA From Above Close Crossing 50 EMA From Above
Close Crossing 100 EMA From Above Close Crossing 100 EMA From Above
Close Crossing 20 EMA From Above Close Crossing 20 EMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 703.00 +2.2%
Divi's Laboratories Ltd. 128,656.69 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,672.65 -1.2%
Cipla Ltd. 71,170.06 883.10 -0.8%
Cadila Healthcare Ltd. 58,547.84 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,028.55 0.0%
Aurobindo Pharma Ltd. 53,214.94 908.25 -0.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 29.59 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 908.25 -0.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 3.88 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 908.25 -0.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 0.18 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 908.25 -0.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 10.09 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 908.25 -0.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 12.53 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 908.25 -0.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 908.25 -0.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 908.25 -0.8%